[ad_1]
La Jolla, California, March 22, 2024–(BUSINESS WIRE)–Equillium, Inc. (NASDAQ: EQ), a clinical-stage biotechnology company focused on developing novel therapies to treat serious autoimmune and inflammatory diseases, today announced that it will attend HC Wainwright Autoimmune and Inflammatory Diseases Exhibition Disease Virtual Conference, LD Micro Invitational Conference.
Management will outline the company’s clinical programs, partnership with Ono Pharmaceuticals and 2024 milestones during both meetings. During the meeting, management will also participate in one-on-one meetings.
Meeting: HC Wainwright Autoimmune and Inflammatory Diseases Virtual Conference
Place: Virtual Fireside Chat
date: Thursday, March 28
time: 11:00 AM Pacific Time | 2:00 PM Eastern Time
Access to the webcast will be provided on the Events and Presentations page under the Investor Relations tab of the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx. Archived replays of meetings will be retained for 90 days.
Meeting: LD Micro Invitational Tournament
Place: Sofitel New York, New York
date: Tuesday, April 9
time: 6:30 AM Pacific Time | 9:30 AM Eastern Time
Demonstrations at the LD Micro conference will be live streamed on the event website https://ldinv14.sequireevents.com/. To access, click “Sign up to watch” and navigate to the Equillium newsletter. Archived replays of the meeting will be retained for 30 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapies to treat serious autoimmune and inflammatory diseases with high unmet medical need. The company’s pipeline includes the following novel first-in-class immunomodulatory assets and product platforms targeting immune-inflammatory pathways. EQ101: Selective trispecific cytokine inhibitor targeting IL-2, IL-9 and IL-15; currently being evaluated in a Phase 2 proof-of-concept clinical study in patients with alopecia areata, funded by Equillium’s Australian subsidiary Conducted in Australia and New Zealand as trial sponsor. EQ302: An oral, selective bispecific cytokine inhibitor targeting IL-15 and IL-21; currently in preclinical development. Multi-cytokine platform: Generate rationally designed complex peptides to selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancy and synergy while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody targeting the CD6-ALCAM signaling pathway, which plays a central role in the regulation of effector T cells; currently in Phase 3 clinical study in patients with acute graft-versus-host disease (aGVHD) and lupus/lupus nephritis patients in a Phase 1b clinical study. Equillium acquired the rights to itolizumab through an exclusive collaboration with Biocon Limited and entered into a strategic partnership with Ono Pharmaceutical Co., Ltd. to develop and commercialize itolizumab under an option and asset purchase agreement.
For more information, please visit www.equilliumbio.com.
forward-looking statements
This press release contains statements that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects.” , “believe,” “can,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict or indicate future events. or trends or statements that are not historical events. Because such statements are subject to risks and uncertainties, many of which are beyond Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that cause forward-looking statements to be uncertain include: Equillium’s ability to execute its plans and strategies; risks associated with conducting clinical studies; and whether the results of clinical studies will validate and support the safety and effectiveness of Equillium’s product candidates. These and other risks and uncertainties are more fully described under the “Risk Factors” heading and elsewhere in Equillium’s filings and reports, which can be accessed free of charge by visiting the SEC’s website: www.sec.gov and information under the heading “Investors” on Equillium’s website. Investors should consider such risks when making investment decisions and should not rely on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they are made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date the statements were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322517281/en/
contact method
Investor Contact
Michael Moore
Vice President of Investor Relations and Corporate Communications
619-302-4431
ir@equilliumbio.com
[ad_2]
Source link